Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). (MELYSA)
Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.
This randomized, controlled multicenter trial will recruit patients aged 18 to 70 years with recurrent nasal polyposis requiring surgery and indication for biologic treatment according to EPOS 2020 guideline. Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment.
All study procedures will be performed in five study visits and may take approximately 30 minutes. Clinical assessments include ifferent questionnaires and nasal endoscopy. This trial includes three treatment arms.
- Combined group (In-office nasal polypectomy group with mepolizumab): This group will undergone in-office nasal polypectomy and will receive Mepolizumab.
- Medical group (mepolizumab): This group will receive Mepolizumab.
- Surgical group (In-office nasal polypectomy): This group will undergone in-office nasal polypectomy. The main advantage is that it allows comparison of mepolizumab versus surgery and surgery/mepolizumab versus surgery + mepolizumab, providing more information on the most effective therapeutic approach.
The presence of adverse effects will be assessed in each treatment arm.
연구 개요
상세 설명
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and indication for biologic treatment according to the criteria of the EPOS2020 guideline.
Presence of bilateral polyps in a patient who had endoscopic sinus surgery (ESS) (except in cases where the patient is not fit for surgery) and three of the following criteria are required:
Evidence of type 2 inflammation (tissue eos> 10/hpf* or blood eos>250, OR total IgE> 100).
* Whenever possible histology from previous surgery should be reviewed to confirm if eosinophilic pathology. If the previous surgery was performed more than 2 years earlier, a blood eosinophil count is essential, as the previous biopsy data may not be relevant.
- Need for systemic corticosteroids or contraindication to systemic steroids (≥ 2 courses per yr, OR long term (>3 months)
- Significantly impaired quality of life (SNOT ≥ 40)
- Significant loss of smell (VAS).
- Diagnosis of comorbid asthma
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
-
Barakaldo, 스페인
- 모병
- Hospital De Cruces
-
연락하다:
- Francisco Valcarcel
- 전화번호: +34946006000
- 이메일: patxivalcarcel@gmail.com
-
Jerez de la Frontera, 스페인
- 모병
- Hospital de Jerez
-
연락하다:
- Alfonso del cuvillo Bernal
- 전화번호: +34956032000
- 이메일: dr.cuvillo@comcadiz.es
-
Madrid, 스페인
- 모병
- Hospital Puerta del Hierro
-
연락하다:
- Antonio Martinez
- 전화번호: +34911916000
- 이메일: amruizcoello@gmail.com
-
Salamanca, 스페인
- 모병
- Hospital de Salamanca
-
연락하다:
- Maria gil
- 전화번호: +34923291100
- 이메일: mgilmel@saludcastillayleon.es
-
Santander, 스페인, 39006
- 모병
- Hospital Universitario Marqués de Valdecilla
-
연락하다:
- david lobo duro
- 전화번호: +34942315515
- 이메일: david.lobo@scsalud.es
-
Seville, 스페인
- 모병
- Hospital Universitario Virgen Macarena
-
연락하다:
- Serafín Sánchez Gómez
- 전화번호: +34955008000
- 이메일: serafin.sanchez.sspa@juntadeandalucia.es
-
Valladolid, 스페인
- 모병
- Hospital de Valladolid
-
연락하다:
- Jaime Santos
- 전화번호: +34983420000
- 이메일: jsp002@gmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Participant 18 years of age or older
Patients with a diagnosis of CRS with polyposis according to the criteria of the EPOS2020 guideline:
Chronic rhinosinusitis with nasal polyps in adults is defined as presence of two or more symptoms, one of which should be either nasal blockage / obstruction / congestion or nasal discharge (anterior / posterior nasal drip); ± facial pain/pressure; ± reduction or loss of smell; for ≥12 weeks; and either endoscopic signs of nasal polyps, and/or CT changes: mucosal changes within the ostiomeatal complex and/or sinuses.
Patients with indication for biologic treatment according to the criteria of the EPOS2020 guideline. Presence of bilateral polyps in a patient who had ESS and three of the following criteria are required:
3.1. Evidence of type 2 inflammation (tissue eos> 10/hpf* or blood eos>250, OR total IgE> 100).
* Whenever possible histology from previous surgery should be reviewed to confirm if eosinophilic pathology. If the previous surgery was performed more than 2 years earlier, a blood eosinophil count is essential, as the previous biopsy data may not be relevant.
3.2. Need for systemic corticosteroids or contraindication to systemic steroids (≥ 2 courses per yr, OR long term (>3 months)
3.3. Significantly impaired quality of life (SNOT ≥ 40)
3.4. Significant loss of smell (≥7 VAS)
3.5. Diagnosis of comorbid asthma
- Basal eosinophil count (BEC) ≥300 cells/µL for surgical naïve patients- or for those who have had surgery and have recurrence . The result of a previous analysis would be valid if it was obtained in a period of time not exceeding one year
- Patients have been informed and signed consent to participate in the study.
Exclusion Criteria:
- Any serious or uncontrolled systemic or psychiatric illness that prevents a correct cognitive or endoscopic assessment or does not advise participation in the study.
- Unilateral localized secondary CRS (odontogenic, fungal ball, tumor).
- Bilateral diffuse secondary CRS (cystic fibrosis; eosinophilic granulomatosis with polyangiitis-S. de Churg-Strauss-; granulomatosis with polyangiitis-S de Wegener-; primary ciliary dyskinesia; selective immunodeficiencies.
- Pregnancy/ breast feeding.
- Hypersensitivity to mepolizumab or its excipients.
- Patients unable to complete the questionnaire or follow prescribed treatment.
- Patients who are participating in another clinical trial related to polyposis or asthma.
- Previously documented failure with IL-5/IL-5 receptor biologics
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: surgical arm
This group of patients will undergo nasal polypectomy in the office and will not receive mepolizumab treatment.
|
polypectomy in the office and will not receive mepolizumab treatment.
|
|
실험적: medical arm
This group of patients will not undergo in-office nasal polypectomy and will start treatment with mepolizumab directly after randomization.
|
will not undergo in-office nasal polypectomy and will start treatment with mepolizumab directly after randomization.
|
|
실험적: combined arm
This group of patients will undergo in-office nasal polypectomy before starting treatment with mepolizumab.
Mepolizumab treatment will be administered at the surgical procedure visit or within 48 hours after the polypectomy.
|
in-office nasal polypectomy before starting treatment with mepolizumab.
Mepolizumab treatment will be administered at the surgical procedure visit or within 48 hours after the polypectomy.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
the efficacy of mepolizumab+polypectomy compared to mepolizumab or polypectomy, using the change from baseline in sinonasal outcome test (SNOT-22) total score at week 52.
기간: 12 moths
|
SNOT-22 total score ranges from 0 to 110, with higher scores indicating worse quality of life/more severe symptoms.
|
12 moths
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in nasal polyposis severity VAS score at V1, V6, V12.
기간: 1 month, 6 months and 12 months
|
VAS score ranges from 0 to 100, with higher scores indicating greater symptom severity.
|
1 month, 6 months and 12 months
|
|
Change in endoscopic nasal polyp score at V1, V6, V12
기간: 1 month, 6 months and 12 months
|
1 month, 6 months and 12 months
|
|
|
Improvement in individual VAS symptoms (rhinorrhea, mucus in throat, nasal blockage, and sense of smell), patient-reported outcomes at V1, V6, V12
기간: 1 month, 6 months and 12 months
|
1 month, 6 months and 12 months
|
|
|
Number of patients no longer requiring rescue systemic corticosteroid treatment throughout the first year after the first month of starting the study
기간: 12 months
|
12 months
|
|
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Related to Mepolizumab and/or In-office Nasal Polypectomy
기간: 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months
|
Adverse events collected at each study visit and classified as serious or non-serious per protocol definitions, and by causal relationship to treatment (unrelated, possible, probable) as assessed by the investigator.
|
1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months
|
|
Change from baseline in sinonasal outcome test (SNOT-22) total score at weeks 4 and 24
기간: 1 month and 12 months
|
1 month and 12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .